{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:08:54Z","timestamp":1789416534536,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["NIH R01 CA256724-A1"],"award-info":[{"award-number":["NIH R01 CA256724-A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008273","name":"Novartis International AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Medical Association"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jnma.2026.06.013","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:24:17Z","timestamp":1785151457000},"page":"894-903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in the treatment of chronic obstructive pulmonary disease"],"prefix":"10.1016","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5100-2872","authenticated-orcid":false,"given":"Sibtain","family":"Moledina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cheriye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Flenaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9405-7475","authenticated-orcid":false,"given":"Marilyn G.","family":"Foreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jnma.2026.06.013_bib0001","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12931-024-03051-2","article-title":"Global, regional, and national burden of chronic obstructive pulmonary disease and its attributable risk factors from 1990 to 2021: an analysis for the Global burden of disease study 2021","volume":"26","author":"Wang","year":"2025","journal-title":"Respir Res"},{"issue":"12","key":"10.1016\/j.jnma.2026.06.013_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46598","article-title":"Global burden of chronic obstructive pulmonary disease through 2050","volume":"6","author":"Boers","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jnma.2026.06.013_sbref0003","series-title":"Chronic Obstructive Pulmonary Disease (COPD) \u2013 Fact Sheet","year":"2024"},{"issue":"11","key":"10.1016\/j.jnma.2026.06.013_bib0004","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1136\/thorax-2022-219158","article-title":"Pulmonary emphysema subtypes defined by unsupervised machine learning on CT scans","volume":"78","author":"Angelini","year":"2023","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jnma.2026.06.013_bib0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.chest.2023.03.007","article-title":"Lung imaging in COPD part 1: clinical usefulness","volume":"164","author":"Raoof","year":"2023","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.jnma.2026.06.013_bib0006","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.chest.2023.02.049","article-title":"Lung imaging in COPD part 2: emerging concepts","volume":"164","author":"Raoof","year":"2023","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.jnma.2026.06.013_bib0007","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/thorax-2024-221928","article-title":"Association between automatic AI-based quantification of airway-occlusive mucus plugs and all-cause mortality in patients with COPD","volume":"80","author":"van der Veer","year":"2025","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jnma.2026.06.013_bib0008","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12931-024-02729-x","article-title":"Local heterogeneity of normal lung parenchyma and small airways disease are associated with COPD severity and progression","volume":"25","author":"Bell","year":"2024","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.jnma.2026.06.013_bib0009","doi-asserted-by":"crossref","first-page":"00289","DOI":"10.1183\/23120541.00289-2023","article-title":"Lung volumes differentiate the predominance of emphysema versus airway disease phenotype in early COPD: an observational study of the COPDGene cohort","volume":"9","author":"Zeng","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jnma.2026.06.013_bib0010","unstructured":"Global strategy for prevention, diagnosis, and management of COPD: 2025 report. Available from: https:\/\/goldcopd.org\/2025-gold-report\/."},{"issue":"8","key":"10.1016\/j.jnma.2026.06.013_bib0011","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jnma.2026.06.013_bib0012","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.jnma.2026.06.013_bib0013","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-glycopyrronium versus Salmeterol-fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jnma.2026.06.013_bib0014","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jnma.2026.06.013_bib0015","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","article-title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","volume":"371","author":"Magnussen","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jnma.2026.06.013_bib0016","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/rccm.201803-0405OC","article-title":"Long-term triple therapy de-escalation to indacaterol\/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial","volume":"198","author":"Chapman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"9691","key":"10.1016\/j.jnma.2026.06.013_bib0017","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"issue":"9971","key":"10.1016\/j.jnma.2026.06.013_bib0018","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(14)62410-7","article-title":"Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial","volume":"385","author":"Martinez","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jnma.2026.06.013_bib0019","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1164\/rccm.201607-1349OC","article-title":"Effect of Roflumilast and inhaled corticosteroid\/long-acting beta2-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial","volume":"194","author":"Martinez","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.jnma.2026.06.013_bib0020","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1164\/rccm.201712-2493OC","article-title":"Determinants of response to Roflumilast in severe chronic obstructive pulmonary disease. Pooled analysis of two randomized trials","volume":"198","author":"Martinez","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.jnma.2026.06.013_bib0021","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/14656566.2025.2491515","article-title":"Ensifentrine: a novel approach to redefining COPD management and implications for additional respiratory diseases","volume":"26","author":"Sciurba","year":"2025","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.jnma.2026.06.013_bib0022","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","article-title":"Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter Phase III trials (the ENHANCE Trials)","volume":"208","author":"Anzueto","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jnma.2026.06.013_bib0023","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1007\/s00210-025-04558-1","article-title":"A comprehensive systematic review and meta-analysis of ensifentrine in COPD: dose-dependent effects, safety profile, and GRADE-based certainty of evidence","volume":"399","author":"Abou Elezz","year":"2026","journal-title":"Naunyn Schmiedeb Arch Pharmacol"},{"issue":"2","key":"10.1016\/j.jnma.2026.06.013_bib0024","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1164\/rccm.202308-1355LE","article-title":"Pharmacological interpretation of the efficacy of ensifentrine in chronic obstructive pulmonary disease: insights from ENHANCE trials","volume":"209","author":"Calzetta","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jnma.2026.06.013_bib0025","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00150-2024","article-title":"Type 2 airway inflammation in COPD","volume":"63","author":"Polverino","year":"2024","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jnma.2026.06.013_bib0026","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/path.5364","article-title":"Recent advances in chronic obstructive pulmonary disease pathogenesis: from disease mechanisms to precision medicine","volume":"250","author":"Brandsma","year":"2020","journal-title":"J Pathol"},{"issue":"11","key":"10.1016\/j.jnma.2026.06.013_bib0027","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jnma.2026.06.013_bib0028","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S2213-2600(24)00299-6","article-title":"Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial","volume":"13","author":"Ramakrishnan","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"17","key":"10.1016\/j.jnma.2026.06.013_bib0029","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jnma.2026.06.013_bib0030","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jnma.2026.06.013_bib0031","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jnma.2026.06.013_bib0032","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2024.05.011","article-title":"Towards precision medicine in COPD: targeting type 2 cytokines and alarmins","volume":"125","author":"Varricchi","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"2","key":"10.1016\/j.jnma.2026.06.013_bib0033","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/15412555.2018.1437897","article-title":"Biologic drugs: a new target therapy in COPD?","volume":"15","author":"Yousuf","year":"2018","journal-title":"COPD"},{"issue":"7","key":"10.1016\/j.jnma.2026.06.013_bib0034","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/all.13760","article-title":"Inflammatory endotypes in COPD","volume":"74","author":"Barnes","year":"2019","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.jnma.2026.06.013_bib0035","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/MCP.0000000000000751","article-title":"How might endotyping guide chronic obstructive pulmonary disease treatment? Current understanding, knowledge gaps and future research needs","volume":"27","author":"Burkes","year":"2021","journal-title":"Curr Opin Pulm Med"},{"issue":"10","key":"10.1016\/j.jnma.2026.06.013_bib0036","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.202209-1748SO","article-title":"Phenotypes, etiotypes, and endotypes of exacerbations of chronic obstructive pulmonary disease","volume":"208","author":"Bhatt","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.jnma.2026.06.013_bib0037","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1164\/rccm.201902-0383OC","article-title":"Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). A multicenter, open-label randomized controlled clinical trial","volume":"200","author":"Criner","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.jnma.2026.06.013_bib0038","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1164\/rccm.201803-0590OC","article-title":"A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (LIBERATE)","volume":"198","author":"Criner","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.jnma.2026.06.013_bib0039","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1159\/000525729","article-title":"Endoscopic valve therapy in COPD patients with hypercapnia","volume":"101","author":"Roetting","year":"2022","journal-title":"Respiration"},{"issue":"9","key":"10.1016\/j.jnma.2026.06.013_bib0040","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1159\/000524996","article-title":"Endoscopic lung volume reduction with one-way valves in patients with severe chronic obstructive pulmonary disease with hypercapnia","volume":"101","author":"Lenga","year":"2022","journal-title":"Respiration"},{"issue":"2","key":"10.1016\/j.jnma.2026.06.013_bib0041","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000505428","article-title":"Endobronchial valve treatment in emphysema patients with a very low DLCO","volume":"99","author":"van Dijk","year":"2020","journal-title":"Respiration"},{"issue":"64","key":"10.1016\/j.jnma.2026.06.013_bib0042","first-page":"875","article-title":"Endobronchial valves for emphysema are effective in patients with moderate hyperinflation in the presence of a clear target lobe. Conference abstract","volume":"56","author":"Klooster","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jnma.2026.06.013_bib0043","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1513\/AnnalsATS.202004-342OC","article-title":"Patient satisfaction and attainment of patient-specific goals after endobronchial valve treatment","volume":"18","author":"Hartman","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.jnma.2026.06.013_bib0044","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/SPC.0000000000000682","article-title":"Recent advances in bronchoscopic lung volume reduction for severe COPD patients","volume":"17","author":"Posthuma","year":"2023","journal-title":"Curr Opin Support Palliat Care"},{"issue":"176","key":"10.1016\/j.jnma.2026.06.013_bib0045","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0258-2024","article-title":"Extrapulmonary effects of lung volume reduction in severe emphysema: a systematic review","volume":"34","author":"Ter Haar","year":"2025","journal-title":"Eur Respir Rev"},{"issue":"4","key":"10.1016\/j.jnma.2026.06.013_bib0046","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1378\/chest.14-1677","article-title":"Executive summary: prevention of acute exacerbation of COPD: American college of chest physicians and Canadian thoracic society guideline","volume":"147","author":"Criner","year":"2015","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.jnma.2026.06.013_bib0047","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1513\/AnnalsATS.202206-545OC","article-title":"Safety and efficacy of inpatient pulmonary rehabilitation for patients hospitalized with an acute exacerbation of chronic obstructive pulmonary disease: systematic review and meta-analyses","volume":"20","author":"Moecke","year":"2023","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.jnma.2026.06.013_bib0048","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/thorax-2023-220333","article-title":"Do pulmonary rehabilitation programmes improve outcomes in patients with COPD posthospital discharge for exacerbation: a systematic review and meta-analysis","volume":"79","author":"Jenkins","year":"2024","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.jnma.2026.06.013_bib0049","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.chest.2023.09.026","article-title":"Pulmonary rehabilitation is associated with decreased exacerbation and mortality in patients with COPD: a nationwide Korean study","volume":"165","author":"Choi","year":"2024","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.jnma.2026.06.013_bib0050","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1164\/rccm.202306-1066ST","article-title":"Pulmonary rehabilitation for adults with chronic respiratory disease: an official American thoracic society clinical practice guideline","volume":"208","author":"Rochester","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 4","key":"10.1016\/j.jnma.2026.06.013_bib0051","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1136\/thorax-2023-220439","article-title":"British thoracic society clinical statement on pulmonary rehabilitation","volume":"78","author":"Man","year":"2023","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.jnma.2026.06.013_bib0052","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1164\/rccm.202204-0643OC","article-title":"Long-term telerehabilitation or unsupervised training at home for patients with chronic obstructive pulmonary disease: a randomized controlled trial","volume":"207","author":"Zanaboni","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jnma.2026.06.013_bib0053","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1513\/AnnalsATS.202405-549OC","article-title":"Telerehabilitation compared to center-based Pulmonary rehabilitation for people with chronic Respiratory disease: economic analysis of a randomized, controlled clinical trial","volume":"22","author":"Burge","year":"2025","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.jnma.2026.06.013_bib0054","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41746-023-00962-0","article-title":"Wearable technology interventions in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"6","author":"Shah","year":"2023","journal-title":"NPJ Digit Med"},{"issue":"18","key":"10.1016\/j.jnma.2026.06.013_bib0055","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1001\/jama.2022.3823","article-title":"Screening for chronic obstructive pulmonary disease: challenges and opportunities","volume":"327","author":"Bhatt","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jnma.2026.06.013_bib0056","article-title":"A multidimensional diagnostic approach for chronic obstructive pulmonary disease","author":"Group","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jnma.2026.06.013_bib0057","doi-asserted-by":"crossref","DOI":"10.1177\/1753465817750524","article-title":"Defining the relationship between COPD and CVD: what are the implications for clinical practice?","volume":"12","author":"Morgan","year":"2018","journal-title":"Ther Adv Respir Dis"},{"issue":"4\u20135","key":"10.1016\/j.jnma.2026.06.013_bib0058","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14779072.2024.2333786","article-title":"Cardiovascular disease and risk in COPD: a state of the art review","volume":"22","author":"Polman","year":"2024","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"10.1016\/j.jnma.2026.06.013_bib0059","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1164\/rccm.202110-2441OC","article-title":"Prognosis of patients with chronic obstructive pulmonary disease not eligible for major clinical trials","volume":"206","author":"Colak","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jnma.2026.06.013_bib0060","doi-asserted-by":"crossref","first-page":"00610","DOI":"10.1183\/23120541.00610-2025","article-title":"Diversity and inclusivity in clinical trial populations for maintenance inhaler therapy in people with COPD: a systematic review","volume":"12","author":"Birch","year":"2026","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jnma.2026.06.013_bib0061","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2147\/COPD.S475875","article-title":"Race-based pulmonary function testing correction in COPD inhaler therapy trials: a systematic review","volume":"19","author":"Wang","year":"2024","journal-title":"Int J Chron Obs Pulmon Dis"},{"issue":"1","key":"10.1016\/j.jnma.2026.06.013_bib0062","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12931-021-01664-5","article-title":"Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes","volume":"22","author":"Pison","year":"2021","journal-title":"Respir Res"},{"issue":"12","key":"10.1016\/j.jnma.2026.06.013_bib0063","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1164\/rccm.202502-0404OC","article-title":"Randomized sham-controlled trial of targeted lung denervation in patients with chronic obstructive pulmonary disease (AIRFLOW-3)","volume":"211","author":"Shah","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.jnma.2026.06.013_bib0064","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1164\/rccm.202502-0378OC","article-title":"Airway scaffolds for emphysema-related hyperinflation: six-month results from the BREATHE trial","volume":"211","author":"Tana","year":"2025","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of the National Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0027968426001082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0027968426001082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:55:45Z","timestamp":1789415745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0027968426001082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0027968426001082"],"URL":"https:\/\/doi.org\/10.1016\/j.jnma.2026.06.013","relation":{},"ISSN":["0027-9684"],"issn-type":[{"value":"0027-9684","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the treatment of chronic obstructive pulmonary disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jnma.2026.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of National Medical Association.","name":"copyright","label":"Copyright"}]}}